Leading CRAC Channel Platform Company Delivering Drug Candidates For Inflammatory Diseases
CRAC Channel Technology
Calcium release-activated calcium channels, or CRAC channels, are responsible for replenishing the calcium stores inside many cell types. Since calcium is an important regulator of multiple biological functions, CRAC channel activation controls several of these functions including inflammation, vascular permeability and cell death.
Auxora Pipeline
CalciMedica is advancing lead product candidate AuxoraTM for the treatment of acute inflammatory conditions such as COVID-19 pneumonia and acute pancreatitis.
News
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the …
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of stroke CRAC channel inhibitors represent an important future …
